Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma (DLCL) is characterized by a marked degree of morphologic and clinical heterogeneity. We studied 156 patients with de novo DLCL for rearrangements of the BCL2, BCL6, and MYC oncogenes by Southern blot analysis and BCL2 protein expression. We related these data to the primary site of presentation, disease stage, and other clinical risk factors. Structural alterations of BCL2, BCL6, and MYC were detected in 25 of 156, 36 of 116, and 10 of 151 patients, respectively. Three cases showed a combination of BCL2 and BCL6 rearrangements, and two cases had a combination of BCL6 and MYC rearrangements. BCL2 rearrangement was found more often in extensive (39%) and primary nodal (17%) lymphomas than in extranodal cases (4%) (P = .003). BCL2 rearrangement was present in none of 40 patients with stage I disease, but in 22% of patients with stage II to IV (P = .006). The presence of BCL2 rearrangements did not significantly affect overall survival (OS) or disease-free survival (DFS). In contrast, high BCL2 protein expression adversely affected both OS (P = .008) and DFS (P = .01). BCL2 protein expression was poorly correlated with BCL2 rearrangement: only 52% of BCL2-rearranged lymphomas and 37% of BCL2-unrearranged cases had high BCL2 protein expression. Rearrangement of BCL6 was found more often in patients with extranodal (36%) and extensive (39%) presentation versus primary nodal disease (28%). No significant correlation was found with disease stage, lymphadenopathy, or bone marrow involvement. DFS and OS were not influenced by BCL6 rearrangements. MYC rearrangements were found in 16% of primary extranodal lymphomas, versus 2% of primary nodal cases (P = .02). In particular, gastrointestinal (GI) lymphomas (5 of 18 cases, 28%) were affected by MYC rearrangements. The distinct biologic behavior of these extranodal lymphomas was reflected by a high complete remission (CR) rate: 7 of 10 patients with MYC rearrangement attained complete remission and 6 responders remained alive for more than 4 years, resulting in a trend for better DFS (P = .07). These data show the complex nature of molecular events in DLCL, which is a reflection of the morphologic and clinical heterogeneity of these lymphomas. However, thus far, these genetic rearrangements fail as prognostic markers.

[1]  M. Ladanyi,et al.  Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. , 1994, The New England journal of medicine.

[2]  E. Jaffe,et al.  Molecular genetics of gastrointestinal non-Hodgkin‧s lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas , 1990 .

[3]  John Calvin Reed,et al.  Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. , 1992, Blood.

[4]  H. Tilly,et al.  LAZ3, a novel zinc–finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas , 1993, Nature Genetics.

[5]  T. Tasaka,et al.  Genomic rearrangement of the c-myc proto-oncogene in non-AIDS-related lymphoma in Japan. , 1991, Leukemia.

[6]  G. Klein,et al.  Characteristic chromosomal abnormalities in biopsies and lymphoid‐cell lines from patients with burkitt and non‐burkitt lymphomas , 1976, International journal of cancer.

[7]  P. Pandolfi,et al.  The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation , 1997, Nature Genetics.

[8]  E. Jaffe,et al.  Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences. , 1995, Blood.

[9]  C. Meijer,et al.  bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Franssila,et al.  BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. , 1997, Blood.

[11]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[12]  D. Longo,et al.  MYC rearrangements in histologically progressed follicular lymphomas. , 1992, Blood.

[13]  A. Zelenetz,et al.  BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. , 1995, Leukemia & lymphoma.

[14]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[15]  F. Behm,et al.  Somatic rearrangement of the c‐myc oncogene in primary human diffuse large‐cell lymphoma , 1986, International journal of cancer.

[16]  S. Poppema,et al.  CLINICAL SIGNIFICANCE OF BCL2- MBR GENE REARRANGEMENT AND PROTEIN EXPRESSION IN DLBCL: AN ANALYSIS OF 83 CASES , 1994 .

[17]  C. Croce,et al.  The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. , 1985, Science.

[18]  H. Ohno,et al.  Rearrangement of the BCL6 gene in B‐cell lymphoid neoplasms: comparison with lymphomas associated with BCL2 rearrangement , 1996, British journal of haematology.

[19]  M. Ladanyi,et al.  MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. , 1991, Blood.

[20]  Prof. Dr. Dr. h.c. mult. Karl Lennert,et al.  Histopathology of Non-Hodgkin’s Lymphomas , 1992, Springer Berlin Heidelberg.

[21]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[22]  L. Young,et al.  Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. , 1995, Blood.

[23]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[24]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[25]  Elaine S. Jaffe,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[26]  D. de Jong,et al.  Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. , 1988, The New England journal of medicine.

[27]  D. Jong,et al.  Essential Differences in Oncogene Involvement Between Primary Nodal and Extranodal Large Cell Lymphoma , 1991 .

[28]  K. Offit,et al.  Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R S Chaganti,et al.  BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  p53 mutations are associated with histologic transformation of follicular lymphoma , 1993 .

[31]  M. Borrello,et al.  Clonal immunoglobulin gene rearrangements and normal T-cell receptor, bcl-2, and c-myc genes in primary cutaneous B-cell lymphomas. , 1989, Cancer research.

[32]  K. Offit,et al.  18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance , 1989, British journal of haematology.

[33]  N. Harris,et al.  bcl‐2 Rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features , 1993, Cancer.

[34]  M. Oken,et al.  bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. , 1989, The New England journal of medicine.

[35]  H. Tilly,et al.  Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma. , 1992, Blood.

[36]  G. Gaidano,et al.  Molecular heterogeneity of B‐lineage diffuse large cell lymphoma , 1996, Genes, chromosomes & cancer.

[37]  K. Offit,et al.  Identification of genetic lesions associated with diffuse large-cell lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  J Hermans,et al.  Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Groudine,et al.  Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. , 1987, Science.

[40]  K. Offit,et al.  Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. , 1994, Blood.

[41]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[42]  S. Poppema,et al.  Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D. Longo,et al.  p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.

[44]  S. Korsmeyer,et al.  Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. , 1998, Blood.

[45]  D. de Jong,et al.  De novo acute B-cell leukemia with translocation t(14;18): an entity with a poor prognosis. , 1991, Leukemia.

[46]  A. Rosenwald,et al.  The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. , 1997, Cancer research.

[47]  D. Smithers.  Summary of papers delivered at the Conference on Staging in Hodgkin's Disease (Ann Arbor). , 1971, Cancer research.

[48]  R. Chaganti,et al.  Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. , 1995, The EMBO journal.

[49]  R. Chaganti,et al.  Hypermutation of the MYC gene in diffuse large cell lymphomas with translocations involving band 8q24 , 1993, Genes, chromosomes & cancer.

[50]  D C Linch,et al.  Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.

[51]  K. Franssila,et al.  DNA copy number changes in diffuse large B-cell lymphoma--comparative genomic hybridization study. , 1996, Blood.

[52]  Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. , 1991 .

[53]  K. Hayashi,et al.  Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. , 1992, Blood.

[54]  M. Raffeld,et al.  Diffuse aggressive B-cell lymphomas of the gastrointestinal tract. An immunophenotypic and gene rearrangement analysis of 22 cases. , 1992, American journal of clinical pathology.

[55]  LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients , 1994 .